All Archives - BaseLaunch

All

How Novo Nordisk partners with academia, biotech companies and beyond

How Novo Nordisk partners with academia, biotech companies and beyond Novo Nordisk began with a one-dollar insulin license. Today, it’s a global giant fighting more…

oliver.stula@baselarea.swiss26.09.2025

All Portfolio news

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Basel, Switzerland - September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its…

oliver.stula@baselarea.swiss24.09.2025

All Portfolio news

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical…

oliver.stula@baselarea.swiss12.08.2025

All Features

BaseLaunch Summer Get-Together 2025

Our summer get-together brought people from across the biotech ecosystem, from founders and scientists, to investors, partners, and beyond, for an evening that combined meaningful…

oliver.stula@baselarea.swiss02.07.2025

All

Navigating US & EU Patent Law for Startups – avoiding the common pitfalls

Navigating US & EU Patent Law for Startups – avoiding the common pitfalls If you want to protect your intellectual property with a patent, you…

oliver.stula@baselarea.swiss28.06.2025

All

Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer

Allschwil, Switzerland – 10 June, 2025 – Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer. Dr. Barker joins Phialogics with…

oliver.stula@baselarea.swiss03.06.2025

All

Filing intellectual property (IP) on novel targets and epitopes

Filing intellectual property (IP) on novel targets and epitopes Building a strong IP portfolio is complex, especially when securing patents for novel targets and epitopes.…

oliver.stula@baselarea.swiss23.04.2025

All

What’s the ideal deal structure to secure funding for biotech startups?

What’s the ideal deal structure to secure funding for biotech startups? As the biotech funding environment evolves, particularly in early seed and Series A rounds,…

andy30.01.2025

All

Alentis announces positive topline results from two studies of Lixudebart

Basel, Switzerland – 9 Jan, 2025, Alentis Therapeutics, a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced positive topline…

andy13.01.2025

All

Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

Basel, Switzerland – 18 Dec, 2024, Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer…

andy18.12.2024

All